Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David A. Rinaldi"'
Publikováno v:
Revista de la Facultad de Odontología. Universidad Nacional de Cuyo; 2023, Vol. 17 Issue 1, p1-7, 7p
Autor:
Glen Mills, Brian C. Barnes, M. Felicia Fontenot, Joseph E. Brierre, James L. Cole, Siva Yadlapati, David A. Rinaldi, Nancy A. Lormand, Eric J. Buller, John M. Rainey
Publikováno v:
Cancer. 95:1274-1278
BACKGROUND Multiple trials have been performed to evaluate second-line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. METHODS Patients
Autor:
David A. Rinaldi, D. Rinaldi, N. Lormand, J. Brierre, J. Cole, B. Barnes, F. Fontenot, E. Buller, J. Rainey
Publikováno v:
Cancer Investigation. 19:467-474
The purposes of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of topotecan (TOP) and gemcitabine (GEM) combination therapy when administered to patients with prev
Autor:
David A. Rinaldi, John M. Rainey, Eric J. Buller, Joseph E. Brierre, M. Patrick Stagg, James L. Cole, Nancy A. Lormand, M. Felicia Fontenot
Publikováno v:
American journal of clinical oncology. 25(5)
The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine and paclitaxel combination therapy when administered to patients with advance
Autor:
Fontenot Mf, James L. Cole, Nancy A. Lormand, David A. Rinaldi, John M. Rainey, Joseph E. Brierre, Eric J. Buller, Stagg Mp
Publikováno v:
American journal of clinical oncology. 23(1)
The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine (GEM) (Gemzar) and 5-fluorouracil (5-FU) combination therapy when administere
Autor:
James L. Cole, David A. Rinaldi, K. B. Roden, Nancy A. Lormand, John M. Rainey, Joseph E. Brierre
Publikováno v:
Journal of Clinical Oncology. 22:2090-2090
2090 Background: GEM and DOC have demonstrated single-agent antitumor activity against a variety of malignancies. Pharmacological studies of GEM have demonstrated that the intracellular concentration of its active triphosphate metabolite is maximized